Physician profile
Anthony Albert Patsy
NPI 1760652655
$68,277.94
in general payments reported to CMS, 2019-2025
39 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $96.72 · 2021: $197 · 2022: $22K · 2023: $22K · 2024: $12K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $4,370 · Travel and Lodging: $823 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,100.00 |
| Food and Beverage | $4,369.81 |
| Travel and Lodging | $822.64 |
| Education | $126.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63,557.68 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $587.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $491.12 | 2022-2025 | |
| Pfizer INC. | $472.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.97 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $289.70 | 2022-2025 | |
| Lilly USA, LLC | $265.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $255.67 | 2022-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $231.73 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Astrazeneca Pharmaceuticals Lp | $217.89 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Vanda Pharmaceuticals INC. | $196.02 | 2025 | Fanapt |
| Exact Sciences Corporation | $136.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $121.72 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.12 | 2024-2025 | Caplyta |
| Amarin Pharma, INC. | $90.17 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $87.67 | 2019-2024 | Capvaxive, Vaxelis, M-M-R II |
| Glaxosmithkline, LLC. | $79.53 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Averitas Pharma INC. | $70.78 | 2023-2024 | Qutenza |
| Collegium Pharmaceutical, INC. | $66.16 | 2024-2025 | Belbuca, Xtampza |
| Axsome Therapeutics, INC. | $65.73 | 2024-2025 | Auvelity |
| Dexcom, INC. | $56.67 | 2019-2024 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $52.66 | 2024-2025 | |
| Antares Pharma, INC. | $50.68 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $49.67 | 2020-2025 | Veozah |
| Sunovion Pharmaceuticals INC. | $43.46 | 2022 | |
| Sanofi-Aventis U.S. LLC | $41.13 | 2019-2021 | |
| Abbott Laboratories | $39.60 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $34.82 | 2019-2025 | Eliquis |
| Sumitomo Pharma America, INC. | $30.07 | 2023-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $22.22 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.68 | 2019 | |
| Aimmune Therapeutics, INC. | $17.05 | 2025 | Zenpep |
| Becton, Dickinson and Company | $16.07 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.62 | 2019 | |
| Sanofi Pasteur INC. | $15.03 | 2023 | |
| Scpharmaceuticals INC. | $14.10 | 2024 | |
| Neurocrine Biosciences, INC. | $13.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.76 | 2025 | Eohilia |
| Endogastric Solutions, INC | $9.99 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Patsy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.